Summary

Peptide Synthesis Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Peptide Synthesis Method (Chemical Synthesis and Non-Chemical Synthesis), Type of Chemical Synthesis (Solid Phase Peptide Synthesis, Liquid Phase Peptide Synthesis and Hybrid Phase Peptide Synthesis), Contract Manufacturing Organization Size (Small, Mid-sized, and Large Companies), Key Geographical Regions (North America, Europe, and Asia-Pacific and Rest of the World)
Report Link: https://www.rootsanalysis.com/reports/peptide-therapeutics-manufacturing/305.html
The peptide synthesis market is valued at USD 2.5 billion in 2023 growing at a CAGR of 5.46% during the forecast period 2023-2035.
Peptides serve as signaling molecules that bind to specific receptors on cell surfaces, initiating intracellular effects that regulate physiological functions and metabolic synthesis of various components. Their significance as therapeutic candidates have grown due to enhanced metabolic stability, target specificity, and affinity. Unlike small molecule drugs and biologics, peptide-based therapeutics present unique challenges in pharmacological research, analytical/process development, impurity research, and structure recognition. The peptide synthesis market has evolved significantly in recent years, driven by the popularity of peptide therapeutics. Currently, over 80 peptide therapeutics have been approved globally for treating various chronic diseases such as cancer, chronic pain, diabetes, HIV infection, multiple sclerosis, and osteoporosis. Moreover, since 2015, more than 630 clinical trials have been underway to evaluate the therapeutic effectiveness of peptide-based therapies. Further, the increasing research activity and demand for peptide-based treatments have led developers to expand their capabilities and upgrade manufacturing equipment. However, peptide synthesis faces challenges including production capacity shortages, prompting developers to outsource complex manufacturing processes to contract service providers to reduce costs and time to market. Pharmaceutical and biotechnology companies are actively collaborating with contract manufacturing organizations (CMOs) offering advanced technology platforms to improve the bioavailability of peptide drugs and enhance synthesis efficacy. Outsourcing demand surged with the entry of semaglutide generics into the peptide synthesis market. GLP-1 peptide API contract manufacturing demand notably rose at a rate of 37% annually during 2017-2023 due to its benefits in treating metabolic disorders like type II diabetes and obesity. These factors present lucrative opportunities for contract manufacturers in the peptide synthesis market in the near future.



Key Market Segments
Type of Synthesis Method Used
Chemical Synthesis Method
Non-Chemical Synthesis Method
Type of Chemical Synthesis Method
Liquid Phase Peptide Synthesis
Solid Phase Peptide Synthesis
Hybrid Phase Peptide Synthesis
Company (CMO) Size
Small
Mid-sized
Large
Geography
North America
Europe
Asia-Pacific and Rest of the World
Research Coverage:
The report studies the peptide synthesis market based on type of synthesis method used, type of chemical synthesis method, company (CMO) size and key geographical regions
The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
The report forecasts the revenue of market segments with respect to three major regions
A comprehensive examination of the current market landscape of contract manufacturers providing peptide synthesis services, including various pertinent parameters such as establishment year, entry year into peptide API manufacturing, company size (number of employees), headquarters location, product type (API, intermediates, FDF / fill-finish), API type, services offered, peptide synthesis method, peptide modification type, purification technology, regulatory certifications, geographical presence, and location of peptide API manufacturing facilities.
Detailed company competitiveness evaluation of peptide synthesis contract manufacturers, considering supplier strength and company competitiveness in terms of type of API, type of service offered, type of synthesis method, purification technique used, scale of operation and geographical presence. In addition, number of peptide modification services offered has also been considered. A comprehensive review of recent developments and initiatives undertaken by contract manufacturers in the peptide synthesis industry. This includes a focus on partnerships, collaborations, and expansion initiatives occurring in the peptide synthesis market from 2014 to October 2023.
An in-depth analysis of ongoing and planned studies concentrating on peptide therapeutics. This analysis encompasses various parameters such as trial registration year, number of enrolled patients, trial phase, status, study design (masking type, intervention model, primary purpose), sponsor/collaborator type, therapeutic area, mechanism of action, clinical trial centers, geography, and patient population.
A detailed examination of the capabilities of peptide synthesis companies in different regions. This analysis considers parameters like the number of Contract Manufacturing Organizations (CMOs), clinical sites, clinical trials, enrolled patients, peptide manufacturing facilities, demand for peptide therapeutics, and installed capacity.
Informed estimates of the annual commercial and clinical demand for peptide therapeutics based on parameters such as target patient population, dosing frequency, and dose strength.
An estimate of the global installed capacity of contract manufacturers in the peptide synthesis market. This analysis considers data reported by industry stakeholders and factors in the distribution of peptide production capacity among companies of different sizes (small, mid-sized, and large), operational scale (preclinical/clinical and commercial), location of manufacturing facility (North America, Europe, and Asia Pacific), and synthesis method (solid phase peptide synthesis and liquid phase peptide synthesis).
An analysis highlighting potential strategic partners based on the likelihood of collaborating with peptide therapeutics developers. These potential partners are shortlisted considering parameters like pipeline strength, pipeline maturity, year of establishment, and company size.
A qualitative examination outlining the key factors that peptide drug developers must consider when deciding whether to produce their products in-house or enlist the services of a Contract Manufacturing Organization (CMO).
An in-depth, region-specific analysis of the total cost of ownership associated with engaging a peptide contract manufacturing service provider. This analysis provides an estimate of both direct and indirect expenses across 10 relevant parameters over a 20-year timeframe.
A review of regulatory guidelines pertaining to peptide synthesis, with a focus on the variations observed across different regions such as the US, Europe, Australia, China, India, Japan, and South Korea. This discussion also addresses the regulatory challenges faced by peptide synthesis companies.
A discourse on industry-related trends, key drivers, and challenges within the peptide synthesis sector, structured within a SWOT framework. This analysis includes a Harvey ball assessment to highlight the relative impact of each SWOT parameter on industry dynamics.

Key Benefits of Buying this Report
The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
The report provides stakeholders with a pulse on the peptide synthesis market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
Key Market Companies
AmbioPharm
CPC Scientific
Creative Peptides
CSBio
Bachem
BCN Peptide
CordenPharma
Senn Chemicals
PolyPeptide
Auspep
Chinese Peptide Company
Hybio Pharmaceuticals
Peptide Institute
ScinoPharm

ページTOPに戻る

Table of Contents

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Considerations
2.6.1. Demographics
2.6.2. Economic Factors
2.6.3. Government Regulations
2.6.4. Supply Chain
2.6.5. COVID Impact / Related Factors
2.6.6. Market Access
2.6.7. Healthcare Policies
2.6.8. Industry Consolidation
2.7. Key Market Segmentations
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Overview of Peptides
5.2.1. Structural Analysis of Peptides
5.2.2. Classification of Peptides
5.2.3. Peptide Synthesis
5.2.4. Emerging Technologies for Peptide Synthesis
5.2.5. Peptide Modification
5.2.5.1. N-terminal Modification
5.2.5.2. Internal Modification
5.2.5.3. C-terminal Modification
5.2.5.4. Other Modifications
5.2.6. Peptide Purification
5.2.6.1. Peptide Purity Guidelines
5.3. Overview of Contract Manufacturing
5.3.1. Need for Outsourcing in the Peptide Manufacturing Industry
5.3.2. General Considerations for Selecting a CMO Partner
5.3.3. Advantages of Outsourcing Manufacturing Operations
5.3.4. Risks and Challenges Associated with Outsourcing of Peptide API Manufacturing
5.4. Future Perspectives
6. REGULATORY LANDSCAPE
6.1. Chapter Overview
6.2. Regulatory Scenario: North America
6.2.1. Scenario in The US
6.2.1.1. Overview
6.2.1.2. General Guidelines for Peptide Manufacturing
6.3. Regulatory Scenario: Europe
6.3.1. Scenario in Europe
6.3.1.1. Overview
6.3.1.2. General Guidelines
6.3.2. Scenario in The UK
6.3.2.1. Overview
6.3.2.2. General Guidelines for Peptide Manufacturing
6.4. Regulatory Scenario: Asia-Pacific
6.4.1. Overview
6.4.2. Scenario in Australian
6.4.2.1. General Guidelines for Peptide Manufacturing
6.4.3. Scenario in Chinese
6.4.3.1. General Guidelines for Peptide Manufacturing
6.4.3.2. Tax-related Modifications in Chinese Pharmaceutical Sector
6.4.4. Scenario in India
6.4.4.1. General Guidelines for Peptide Manufacturing
6.4.4.2. Tax-related Modifications in Indian Pharmaceutical Sector
6.4.5. Scenario in Japan
6.4.5.1. General Guidelines for Peptide Manufacturing
6.4.6. Scenario in South Korea
6.4.6.1. General Guidelines for Peptide Manufacturing
6.5. Challenges Associated with Peptide Manufacturing
7. MARKET LANDSCAPE
7.1 Chapter Overview
7.2 Peptide Therapeutics Contract API Manufacturing: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Year of Entrance of Peptide API Contract Manufacturers
7.2.3. Analysis by Company Size
7.2.4. Analysis by Location of Headquarters
7.2.5. Analysis by Type of Product
7.2.6. Analysis by Type of API Manufactured
7.2.7. Analysis by Scale of Operation
7.2.8. Analysis by Type of Services Offered
7.2.9. Analysis by Type of Peptide Synthesis Method
7.2.10. Analysis by Type of Peptide Modification
7.2.11. Analysis by Type of Purification Technology Used
7.2.12. Analysis by Regulatory Certifications and Accreditations
7.2.13. Analysis by Geographical Presence
7.2.14. Analysis by Location of Peptide API Manufacturing Facilities
7.3. List of Custom Peptide Manufacturers
8. COMPANY COMPETITIVENSS ANALYSIS
8.1. Chapter Overview
8.2. Key Parameters
8.3. Methodology
8.4. Company Competitiveness Analysis
8.4.1 Peptide Therapeutics Contract API Manufacturers with Low Manufacturing Capacity
8.4.2 Peptide Therapeutics Contract API Manufacturers with Medium Manufacturing Capacity
8.4.2 Peptide Therapeutics Contract API Manufacturers with High Manufacturing Capacity
9. COMPANY PROFILES
9.1 Chapter Overview
9.2. Peptide Therapeutics Contract API Manufacturers based in North America
9.2.1. AmbioPharm
9.2.1.1. Company Overview
9.2.1.2. Service Portfolio
9.2.1.3. Manufacturing Facilities and Capabilities
9.2.1.4. Recent Developments and Future Outlook
9.2.2. CPC Scientific
9.2.2.1. Company Overview
9.2.2.2. Service Portfolio
9.2.2.3. Manufacturing Facilities and Capabilities
9.2.2.4. Recent Developments and Future Outlook
9.2.3. Creative Peptides
9.2.3.1. Company Overview
9.2.3.2. Service Portfolio
9.2.3.3. Manufacturing Facilities and Capabilities
9.2.3.4. Recent Developments and Future Outlook
9.2.4. CSBio
9.2.4.1. Company Overview
9.2.4.2. Service Portfolio
9.2.4.3. Manufacturing Facilities andCapabilities
9.2.4.4. Recent Developments and Future Outlook
9.3. Peptide Therapeutics Contract API Manufacturers based in Europe
9.3.1. Bachem
9.3.1.1. Company Overview
9.3.1.2. Service Portfolio
9.3.1.3. Manufacturing Facility and Capabilities
9.3.1.4. Recent Developments and Future Outlook
9.3.2. BCN Peptides
9.3.2.1. Company Overview
9.3.2.2. Service Portfolio
9.3.2.3. Manufacturing Facility andCapabilities
9.3.2.4. Recent Development and Future Outlook
9.3.3. CordenPharma
9.3.3.1. Company Overview
9.3.3.2. Service Portfolio
9.3.3.3. Manufacturing Facility and Capabilities
9.3.3.4. Recent Developments and Future Outlook
9.3.4. PolyPeptide
9.3.4.1. Company Overview
9.3.4.2. Service Portfolio
9.3.4.3. Manufacturing Facilities and Capabilities
9.3.4.4. Recent Developments and Future Outlook
9.3.5. Senn Chemicals
9.3.5.1. Company Overview
9.3.5.2. Service Portfolio
9.3.5.3. Manufacturing Facilities and Capabilities
9.3.5.4. Recent Developments and Future Outlook
9.4. Peptide Therapeutics Contract API Manufacturers based in Asia-Pacific
9.4.1. Auspep
9.4.1.1. Company Overview
9.4.1.2. Service Portfolio
9.4.1.3. Manufacturing Facilities and Capabilities
9.4.1.4. Recent Developments and Future Outlook
9.4.2. Chinese Peptide
9.4.2.1. Company Overview
9.4.2.2. Service Portfolio
9.4.2.3. Manufacturing Facilities and Capabilities
9.4.2.4. Recent Developments and Future Outlook
9.4.3. Hybio Pharmaceutical
9.4.3.1. Company Overview
9.4.3.2. Service Portfolio
9.4.3.3. Manufacturing Facilities and Capabilities
9.4.3.4. Recent Developments and Future Outlook
9.4.4. Peptide Institute
9.4.4.1. Company Overview
9.4.4.2. Service Portfolio
9.4.4.3. Manufacturing Facilities and Capabilities
9.4.4.4. Recent Developments and Future Outlook
9.4.5. ScinoPharm
9.4.5.1. Company Overview
9.4.5.2. Service Portfolio
9.4.5.3. Manufacturing Facilities and Capabilities
9.4.5.4. Recent Developments and Future Outlook
10. RECENT DEVELOPMENTS AND INITIATIVES
10.1. Chapter Overview
10.2. Partnerships and Collaborations
10.2.1. Partnerships Models
10.2.2. List of Partnerships and Collaborations
10.2.3. Analysis by Year of Partnership
10.2.4. Analysis by Type of Partnership
10.2.5. Analysis by Year and Type of Partnership
10.2.6. Analysis by Company Size and Type of Partnership
10.2.7. Analysis by Scale of Operation
10.2.8. Analysis by Scale of Operation and Type of Partnership
10.2.9. Analysis by Green Chemistry Integration
10.2.10. Most Active Players: Analysis by Number of Partnerships
10.2.11. Analysis by Geography
10.2.11.1. Intercontinental and Intracontinental Agreements
10.2.12.2. Local and International Agreements
10.3. Recent Expansion Models
10.3.1. Expansion Models
10.3.2 List of Recent Expansions
10.3.3. Analysis by Year of Expansion
10.3.4. Analysis by Type of Expansion
10.3.5. Analysis by Year and Type of Expansion
10.3.6. Analysis by Location of Expanded Facility (Region)
10.3.7. Analysis by Location of Expanded Facility (Country)
10.3.8. Recent Expansions: Analysis by Location of Expanded Facility and Type of Expansion
10.3.9. Most Active Players: Analysis by Number of Expansions
10.3.10. Recent Expansions: Analysis by Geography (Country)
10.3.11. Recent Expansions: List of Planned Expansions
10.4. Emerging Peptide Synthesis Technologies
10.4.1. Chemo-Enzymatic Peptide Synthesis Technology
10.4.2. Continuous Flow Technology
10.4.3. Green Chemistry
11. CLINICAL TRIAL ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Peptide Therapeutics: Clinical Trials Analysis
11.3.1. Analysis by Trial Registration Year
11.3.2. Analysis by Number of Patients Enrolled
11.3.3. Analysis by Trial Phase
11.3.4. Analysis by Trial Registration Year and Trial Phase
11.3.5. Analysis by Trial Phase and Patients Enrolled
11.3.6. Analysis by Trial Status
11.3.7. Analysis by Trial Registration Year and Trial Status
11.3.8. Analysis by Therapeutic Area
11.3.9. Analysis by Mechanism of Action
11.3.10. Analysis by Trial Registration Year and Mechanism of Action
11.3.11. Analysis by Type of Sponsor / Collaborator
11.3.12. Analysis by Study Design
11.3.12.1. Analysis by Type of Patient Allocation Model Used
11.3.12.2. Analysis by Type of Trial Masking Adopted
11.3.12.3. Analysis by Type of Intervention
11.3.12.4. Analysis by Trial Purpose
11.3.13. Most Active Players: Analysis by Number of Clinical Trials
11.3.14. Analysis by Geography
11.3.14.1. Analysis of Clinical Trials by Geography
11.3.14.2. Analysis of Clinical Trials by Geography and Trial Status
11.3.14.3. Analysis of Clinical Trials by Geography and Therapeutic Area
11.3.14.4. Analysis of Patients Enrolled by Geography
11.3.14.5. Analysis of Patients Enrolled by Geography and Trial Status
12. REGIONAL CAPABILITY ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Overall Landscape of Peptide Therapeutics Contract API Manufacturing Facilities
12.4. Peptide Therapeutics Contract API Manufacturing Capability in North America
12.5. Peptide Therapeutics Contract API Manufacturing Capability in Europe
12.6. Peptide Therapeutics Contract API Manufacturing Capability in Asia-Pacific
13. DEMAND ANALYSIS
13.1. Chapter Overview
13.2. Assumptions and Methodology
13.3. Peptide Therapeutics Contract API Manufacturing: Overall Annual Demand
13.3.1. Peptide Therapeutics Contract API Manufacturing: Clinical Demand
13.3.1.1. Clinical Demand for Peptide Therapeutics Contract API Manufacturing: Analysis by Phase of Development
13.3.2. Peptide Therapeutics Contract API Manufacturing: Commercial Outsourced Demand
13.3.2.1. Commercial Demand for Peptide Therapeutics Contract API Manufacturing: Analysis by GLP-1 Mechanism of Action
13.3.3. Peptide Therapeutics Contract API Manufacturing: Analysis by Type of Peptide API Synthesis
13.3.4. Peptide Therapeutics Contract API Manufacturing: Analysis by Geography
14. CAPACITY ANALYSIS
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Peptide Therapeutics Contract API Manufacturing: Global Installed Capacity
14.3.1. Analysis by Company Size
14.3.2. Analysis by Scale of Operation
14.3.3. Analysis by Location of Manufacturing Facility
14.3.4. Analysis by Company Size and Location of Manufacturing Facility
14.3.5 Analysis by Chemical Synthesis Method
14.4. Concluding Remarks
15. LIKELY PARTNERS ANLAYSIS
15.1. Chapter Overview
15.2. Scoring Criteria and Key Assumptions
15.3. Scope and Methodology
15.4. Potential Strategic Partners for Peptide Therapeutics Contract Manufacturers in North America
15.4.1. Most Likely Partners
15.4.2. Likely Partners
15.4.3. Least Likely Partners
15.5. Potential Strategic Partners for Peptide Therapeutics Contract Manufacturers in Europe
15.5.1. Most Likely Partners
15.5.2. Likely Partners
15.5.3. Least Likely Partners
15.6. Potential Strategic Partners for Peptide Therapeutics Contract Manufacturers in Asia Pacific and Rest of the World
15.6.1. Most Likely Partners
15.6.2. Likely Partners
15.6.3. Least Likely Partners
16. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
16.1. Chapter Overview
16.2. Assumptions and Parameter Definitions
16.3. Make versus Buy Decision Making Framework
16.3.1. Scenario 1
16.3.2. Scenario 2
16.3.3. Scenario 3
16.3.4. Scenario 4
16.4. Concluding Remarks
17. TOTAL COST OF OWNERSHIP FOR PEPTIDE CONTRACT MANUFACTURING ORGANIZATIONS
17.1. Chapter Overview
17.2. Assumptions and Methodology
17.3. Key Parameters
17.4. Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization, Y0-Y20
17.5. Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization: Analysis by CAPEX And OPEX, Y0 and Y20
17.5.1. Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization: Analysis by CAPEX, Y0
17.5.2. Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization: Analysis by OPEX, Y1-Y20
18. GLOBAL PEPTIDE THERAPEUTICS CONTRACT API MANUFACTURING MARKET
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Global Peptide Therapeutics Contract API Manufacturing Market, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
18.3.1. Scenario Analysis
18.3.1.1. Conservative Scenario
18.3.1.2. Optimistic Scenario
18.4. Key Market Segmentations
19. PEPTIDE THERAPEUTICS CONTRACT API MANUFACTURING MARKET, BY TYPE OF PEPTIDE SYNTHESIS METHOD
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Type of Peptide Synthesis Method, 2023 and 2035
19.3.1. Non-chemical Synthesis Method Market: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
19.3.2. Chemical Synthesis Method Market: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
19.3.2.1 Liquid Phase Synthesis: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
19.3.2.2 Solid Phase Synthesis: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
19.3.2.3 Hybrid Phase Synthesis: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
19.4. Data Triangulation and Validation
20. PEPTIDE THERAPEUTICS CONTRACT API MANUFACTURING MARKET, BY COMPANY SIZE
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Company Size, 2023 and 2035
20.3.1. Small Company: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
20.3.2. Mid-sized Company: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
20.3.3. Large Company: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
20.4. Data Triangulation and Validation
21. PEPTIDE THERAPEUTICS CONTRACT API MANUFACTURING MARKET, BY GEOGRAPHY
21.1. Chapter Overview
21.2. Assumptions and Methodology
21.3. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Geography, 2024 and 2035
21.3.1. Peptide Therapeutics Contract API Manufacturing Market in North America: Historical Trends (2021-2024) and Forecasted Estimates (2024-2035)
21.3.1.1. Peptide Therapeutics Contract API Manufacturing Market for Small Companies in North America
21.3.1.2. Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in North America
21.3.1.3. Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in North America
21.3.1.4. Peptide Therapeutics Contract API Manufacturing Market in North America for Chemical Synthesis Method
21.3.1.5. Peptide Therapeutics Contract API Manufacturing Market in North America for Non-Chemical Synthesis Method
21.3.2. Peptide Therapeutics Contract API Manufacturing Market in Europe: Historical Trends (2021-2024) and Forecasted Estimates (2024-2035)
21.3.2.1. Peptide Therapeutics Contract API Manufacturing Market for Small Companies in Europe
21.3.2.2. Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in Europe
21.3.2.3. Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in Europe
21.3.2.4. Peptide Therapeutics Contract API Manufacturing Market in Europe for Chemical Synthesis Method
21.3.2.5. Peptide Therapeutics Contract API Manufacturing Market in Europe for Non-Chemical Synthesis Method
21.3.3. Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World: Historical Trends (2021-2024) and Forecasted Estimates (2024-2035)
21.3.3.1. Peptide Therapeutics Contract API Manufacturing Market for Small Companies in Asia-Pacific and Rest of the World
21.3.3.2. Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in Asia-Pacific and Rest of the World
21.3.3.3. Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in Asia-Pacific and Rest of the World
21.3.3.4. Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World for Chemical Synthesis Method
21.3.3.5. Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World for Non-Chemical Synthesis Method
21.4. Data Triangulation and Validation
22. SWOT ANALYSIS
22.1. Chapter Overview
22.2. Strengths
22.3. Weaknesses
22.4. Opportunities
22.5. Threats
22.6. Comparison of SWOT Factors
22.7. Concluding Remarks
23. CONCLUSION
24. EXECUTIVE INSIGHTS
24.1. Chapter Overview
24.2. Ascendia Pharmaceuticals
24.2.1 Company Snapshot
24.2.2. Interview Transcript: Robert Bloder (Chief Business Officer), Shaukat Ali (Senior Director of Scientific Affairs and Technical Marketing)
24.3. Almac
24.3.1 Company Snapshot
24.3.2. Interview Transcript: Alastair Hay (Vice President, Peptides)
24.4. NUMAFERM
24.4.1 Company Snapshot
24.4.2. Interview Transcript: Philipp Burling (Chief Financial Officer)
24.5. Sekisui XenoTech
24.5.1 Company Snapshot
24.5.2. Interview Transcript: Hideki Kubota (Senior Manager, Peptide Business Project Leader)
24.6. Previtalica
24.6.1 Company Snapshot
24.6.2. Interview Transcript: Sergiy Stupka (Founder and Owner)
25. APPENDIX I: TABULATED DATA
26. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

ページTOPに戻る

List of Tables/Graphs

Table 5.1 Comparison of Major Peptide Synthesizing Processes
Table 5.2 Chromatographic Techniques
Table 6.1 Comparison of Regulatory Landscape of China and India
Table 7.1 Peptide Therapeutics Contract API Manufacturers: List of Companies
Table 7.2 Peptide Therapeutics Contract API Manufacturers: Information on Type of API and Scale of Operation
Table 7.3 Peptide Therapeutics Contract API Manufacturers: Information on Type of Services Offered and Peptide Synthesis Method
Table 7.4 Peptide Therapeutics Contract API Manufacturers: Information on Type of Peptide Modification and Type of Purification Technology Used
Table 7.5 Peptide Therapeutics Contract API Manufacturers: Information on Regulatory Certifications and Accreditations
Table 7.6 List of Custom Peptide Manufacturers
Table 8.1 Company Competitiveness Analysis: Peptide Therapeutics Contract API Manufacturers with Low Manufacturing Capacity
Table 8.2 Company Competitiveness Analysis: Peptide Therapeutics Contract API Manufacturers with Medium Manufacturing Capacity
Table 8.3 Company Competitiveness Analysis: Peptide Therapeutics Contract API Manufacturers with High Manufacturing Capacity
Table 9.1 Leading Peptide Therapeutics Contract API Manufacturers
Table 9.2 AmbioPharm: Company Overview
Table 9.3 AmbioPharm: Overview of Manufacturing Capabilities
Table 9.4 AmbioPharm: Recent Developments and Future Outlook
Table 9.5 CPC Scientific: Company Overview
Table 9.6 CPC Scientific: Overview of Manufacturing Capabilities
Table 9.7 CPC Scientific: Recent Developments and Future Outlook
Table 9.8 Creative Peptides: Company Overview
Table 9.9 Creative Peptides: Overview of Manufacturing Capabilities
Table 9.10 Creative Peptides: Recent Developments and Future Outlook
Table 9.11 CSBio: Company Overview
Table 9.12 CSBio: Overview of Manufacturing Capabilities
Table 9.13 CSBio: Recent Developments and Future Outlook
Table 9.14 Bachem: Company Overview
Table 9.15 Bachem: Overview of Manufacturing Capabilities
Table 9.16 Bachem: Recent Developments and Future Outlook
Table 9.17 BCN Peptides: Company Overview
Table 9.18 BCN Peptides: Overview of Manufacturing Capabilities
Table 9.19 BCN Peptides: Recent Developments and Future Outlook
Table 9.20 CordenPharma: Company Overview
Table 9.21 CordenPharma: Overview of Manufacturing Capabilities
Table 9.22 CordenPharma: Recent Developments and Future Outlook
Table 9.23 PolyPeptide: Company Overview
Table 9.24 PolyPeptide: Overview of Manufacturing Capabilities
Table 9.25 PolyPeptide: Recent Developments and Future Outlook
Table 9.26 Senn Chemicals: Company Overview
Table 9.27 Senn Chemicals: Overview of Manufacturing Capabilities
Table 9.28 Auspep: Company Overview
Table 9.29 Auspep: Overview of Manufacturing Capabilities
Table 9.30 Auspep: Recent Developments and Future Outlook
Table 9.31 Chinese Peptide: Company Overview
Table 9.32 Chinese Peptide: Overview of Manufacturing Capabilities
Table 9.33 Hybio Pharmaceuticals: Company Overview
Table 9.34 Hybio Pharmaceuticals: Overview of Manufacturing Capabilities
Table 9.35 Peptide Institute: Company Overview
Table 9.36 Peptide Institute: Overview of Manufacturing Capabilities
Table 9.37 ScinoPharm: Company Overview
Table 9.38 ScinoPharm: Overview of Manufacturing Capabilities
Table 10.1 Peptide Therapeutics Contract API Manufacturers: List of Partnerships and Collaborations, Pre-2019-2023
Table 10.2 Partnerships and Collaborations: Information on Type of Agreement (Country-wise and Region-wise)
Table 10.3 Peptide Therapeutics Contract API Manufacturers: List of Recent Expansions, Pre-2019-2023
Table 10.4 Peptide Therapeutics Contract API Manufacturers: List of Planned Upcoming Expansions
Table 14.1 Peptide Therapeutics Contract API Manufacturers: Information on Total Installed Capacity (Sample Dataset)
Table 14.2 Peptide Therapeutics Contract API Manufacturing: Average Capacity based on Company Size (Sample Dataset)
Table 14.3 Peptide Therapeutics Contract API Manufacturing Capacity: Average Share Based on Synthesis Method (Sample Dataset)
Table 14.4 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Company Size (liters)
Table 15.1 Most Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in North America
Table 15.2 Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in North America
Table 15.3 Least Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in North America
Table 15.4 Most Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in Europe
Table 15.5 Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in Europe
Table 15.6 Least Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in Europe
Table 15.7 Most Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in Asia Pacific and Rest of the World
Table 15.8 Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in Asia Pacific and Rest of the World
Table 15.9 Least Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in Asia Pacific and Rest of the World
Table 24.1 Ascendia Pharmaceuticals: Company Snapshot
Table 24.2 Almac: Company Snapshot
Table 24.3 NUMAFERM: Company Snapshot
Table 24.4 Sekisui: Company Snapshot
Table 24.5 Previtalica: Company Snapshot
Table 25.1 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Year of Establishment
Table 25.2 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Year of Entrance
Table 25.3 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Company Size
Table 25.4 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Location of Headquarters
Table 25.5 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Type of Product
Table 25.6 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Type of API Manufactured
Table 25.7 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Scale of Operation
Table 25.8 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Type of Service Offered
Table 25.9 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Peptide Synthesis Method
Table 25.10 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Chemical Synthesis Method
Table 25.11 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Type of Peptide Modification
Table 25.12 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Type of Purification Technology Used
Table 25.13 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Regulatory Certifications and Accreditations
Table 25.14 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Geographical Presence (Region)
Table 25.15 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Location of Peptide API Manufacturing Facilities (Region)
Table 25.16 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Location of Peptide API Manufacturing Facilities (Country)
Table 25.17 Partnerships andCollaborations: Cumulative Year-wise Trend, Pre-2019-2023
Table 25.18 Partnerships and Collaborations: Distribution by Type of Partnership
Table 25.19 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 25.20 Partnerships and Collaborations: Distribution by Company Size and Type of Partnership
Table 25.21 Partnerships and Collaborations: Distribution by Scale of Operation
Table 25.22 Partnerships and Collaborations: Distribution by Scale of Operation and Type of Partnership
Table 25.23 Partnerships and Collaborations: Distribution by Green Chemistry Integration\
Table 25.24 Most Active Players: Distribution by Number of Partnerships
Table 25.25 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 25.26 Partnerships and Collaborations: Local and International Agreements
Table 25.27 Recent Expansions: Cumulative Year-wise Trend of Recent Expansions, Pre-2019-2023
Table 25.28 Recent Expansions: Distribution by Type of Expansion
Table 25.29 Recent Expansions: Distribution by Year and Type of Expansion
Table 25.30 Recent Expansions: Distribution by Location of Expanded Facility (Region)
Table 25.31 Recent Expansions: Distribution by Location of Expanded Facility (Country)
Table 25.32 Recent Expansions: Distribution by Location of Expanded Facility and Type of Expansion
Table 25.33 Most Active Players: Distribution by Number of Expansions
Table 25.34 Recent Expansions: Distribution by Geography (Country)
Table 25.35 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
Table 25.36 Clinical Trial Analysis: Year-wise Trend of Number of Patients Enrolled by Trial Registration Year
Table 25.37 Clinical Trial Analysis:Distribution by Trial Phase
Table 25.38 Clinical Trial Analysis:Distribution by Trial Phase and Number of Patients Enrolled
Table 25.39 Clinical Trial Analysis:Distribution by Trial Status
Table 25.40 Clinical Trial Analysis:Distribution by Trial Registration Year and Trial Status
Table 25.41 Clinical Trial Analysis:Distribution by Therapeutic Area
Table 25.42 Clinical Trial Analysis:Distribution by Mechanism of Action
Table 25.43 Clinical Trial Analysis:Distribution by Trial Registration Year and Mechanism of Action
Table 25.44 Clinical Trial Analysis:Distribution by Type of Sponsor / Collaborator
Table 25.45 Clinical Trial Analysis:Distribution by Type of Patient Allocation Model Used
Table 25.46 Clinical Trial Analysis:Distribution by Type of Trial Masking Adopted
Table 25.47 Clinical Trial Analysis:Distribution by Type of Intervention Model
Table 25.48 Clinical Trial Analysis:Distribution by Trial Purpose
Table 25.49 Most Active Industry Players:Distribution by Number of Clinical Trials
Table 25.50 Most Active Non-industryPlayers: Distribution by Number of Clinical Trials
Table 25.51 Clinical Trial Analysis:Distribution of Clinical Trials by Geography
Table 25.52 Clinical Trial Analysis:Distribution of Clinical Trials by Geography and Trial Status
Table 25.53 Clinical Trial Analysis:Distribution by Geography and Therapeutic Area
Table 25.54 Clinical Trial Analysis:Distribution of Patients Enrolled by Geography
Table 25.55 Clinical Trial Analysis:Distribution of Patients Enrolled by Geography and Trial Status
Table 25.56 Regional Distribution of Peptide Therapeutics Contract API Manufacturing Facilities
Table 25.57 Regional Capability Analysis: Regional Capability Analysis: Peptide API Contract Manufacturers in North America
Table 25.58 Regional Capability Analysis: Regional Capability Analysis: Peptide API Contract Manufacturers in Europe
Table 25.59 Regional Capability Analysis: Peptide API Contract Manufacturers in Asia Pacific and Rest of the World
Table 25.60 Global Demand for Peptide Therapeutics Contract API Manufacturing, Historical Trends (2017-2023) and Forecasted Estimates (2024-2035) (Kilograms)
Table 25.61 Global Clinical Demand forPeptide Therapeutics Contract API Manufacturing, Historical Trends (2017-2023) and Future Estimates (2024-2035) (Kilograms)
Table 25.62 Clinical Demand for PeptideTherapeutics Contract API Manufacturing: Distribution by Phase of Development, 2024 and 2035
Table 25.63 Clinical Demand for PeptideTherapeutics Contract API Manufacturing for Phase I Trials, 2024-2035 (Kilograms)
Table 25.64 Clinical Demand for PeptideTherapeutics Contract API Manufacturing for Phase II Trials, 2024-2035 (Kilograms)
Table 25.65 Clinical Demand for PeptideTherapeutics Contract API Manufacturing for Phase III Trials, 2024-2035 (Kilograms)
Table 25.66 Global Commercial Demandfor Peptide Therapeutics Contract API Manufacturing, Historical Trends (2017-2023) and Forecasted Estimates (2024-2035) (Kilograms)
Table 25.67 Commercial Demand for Peptide Therapeutics Contract API Manufacturing: Distribution by Mechanism of Action (specific to GLP-1),
Table 25.68 Commercial Demand for Peptide Therapeutics Contract API Manufacturing for GLP-1 Drugs, Historical Trends (2017-2023) and Forecasted Estimates (2024-2035)
Table 25.69 Commercial Demand for Peptide Therapeutics Contract API Manufacturing for non-GLP-1 based Drugs, Historical Trends (2017-2023) and Forecasted Estimates (2024-
Table 25.70 Global Demand for Peptide Therapeutics Contract API Manufacturing: Distribution by Type of Peptide Synthesis Method, 2024 and 2035
Table 25.71 Global Demand for Peptide Therapeutics Contract API Manufacturing: Distribution by Geography, 2024 and 2035 (Kilograms)
Table 25.72 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Company Size (liters)
Table 25.73 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Range of Installed Capacity (liters)
Table 25.74 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Scale of Operation (liters)
Table 25.75 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Location of Manufacturing Facility (liters)
Table 25.76 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Company Size and Location of Manufacturing
Table 25.77 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Synthesis Method (liters)
Table 25.78 Total Cost of Ownership forPeptide Therapeutics Contract API Manufacturing Organization, Y0-Y20 (USD Million)
Table 25.79 Total Cost of Ownership forPeptide Therapeutics Contract API Manufacturing Organization: Distribution by CAPEX and OPEX, Y0 and Y20 (USD Million)
Table 25.80 Total Cost of Ownership forPeptide Therapeutics Contract API Manufacturing Organization, Y0: Distribution by CAPEX (USD Million)
Table 25.81 Total Cost of Ownership forPeptide Therapeutics Contract API Manufacturing Organization, Y1-Y20: Distribution by OPEX (USD Million)
Table 25.82 Global Peptide TherapeuticsContract API Manufacturing Market, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 25.83 Global Peptide Therapeutics Contract API Manufacturing Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Billion)
Table 25.84 Global Peptide Therapeutics Contract API Manufacturing Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Billion)
Table 25.85 Peptide Therapeutics Contract API Manufacturing Market: Distribution by Type of Peptide Synthesis Method, 2024 And 2035
Table 25.86 Peptide Therapeutics Contract API Manufacturing Market for Type of Non-chemical Synthesis, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD
Table 25.87 Peptide Therapeutics Contract API Manufacturing Market for Type of Chemical Synthesis, Historical Trends (2021-2023) and Forecasted Estimates
Table 25.88 Peptide Therapeutics Contract API Manufacturing Market for Liquid Phase Synthesis, Historical Trends (2021-2023) and Forecasted Estimates
Table 25.89 Peptide Therapeutics Contract API Manufacturing Market for Solid Phase Synthesis, Historical Trends (2021-2023) and Forecasted Estimates
Table 25.90 Peptide Therapeutics Contract API Manufacturing Market for Hybrid Phase Synthesis, Historical Trends (2021-2023) and Forecasted Estimates
Table 25.91 Peptide Therapeutics Contract API Manufacturing Market: Distribution by Company Size, 2024 And 2035
Table 25.92 Peptide Therapeutics Contract API Manufacturing Market for Small Companies, Historical Trends (2021-2023) and Forecasted Estimates (2024-
Table 25.93 Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies, Historical Trends (2021-2023) and Forecasted Estimates
Table 25.94 Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD
Table 25.95 Peptide Therapeutics Contract API Manufacturing Market: Distribution by Geography, 2024 And 2035
Table 25.96 Peptide Therapeutics Contract API Manufacturing Market in North America, Historical Trends (2021-2024) and Forecasted Estimates (2024-
Table 25.97 Peptide Therapeutics Contract API Manufacturing Market for Small Companies in North America, 2024-2035 (USD Billion)
Table 25.98 Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in North America, 2024-2035 (USD Billion)
Table 25.99 Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in North America, 2024-2035 (USD Billion)
Table 25.100 Peptide TherapeuticsContract API Manufacturing Market in North America for Chemical Synthesis Method, 2024-2035 (USD Billion)
Table 25.101 Peptide TherapeuticsContract API Manufacturing Market in North America for Non-Chemical Synthesis Method, 2024-2035 (USD Billion)
Table 25.102 Peptide TherapeuticsContract API Manufacturing Market in Europe, Historical Trends (2021-2024) and Forecasted Estimates (2024-2035) (USD Billion)
Table 25.103 Peptide TherapeuticsContract API Manufacturing Market for Small Companies in Europe, 2024-2035 (USD Billion)
Table 25.104 Peptide TherapeuticsContract API Manufacturing Market for Mid-sized Companies in Europe, 2024-2035 (USD Billion)
Table 25.105 Peptide TherapeuticsContract API Manufacturing Market for Large and Very Large Companies in Europe, 2024-2035 (USD Billion)
Table 25.106 Peptide TherapeuticsContract API Manufacturing Market in Europe for Chemical Synthesis Method, 2024-2035 (USD Billion)
Table 25.107 Peptide TherapeuticsContract API Manufacturing Market in Europe for Non-Chemical Synthesis Method, 2024-2035 (USD Billion)
Table 25.108 Peptide TherapeuticsContract API Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (2021-2024) and Forecasted Estimates (2024-
Table 25.109 Peptide TherapeuticsContract API Manufacturing Market for Small Companies in Asia-Pacific and Rest of the World, 2024-2035 (USD Billion)
Table 25.110 Peptide TherapeuticsContract API Manufacturing Market for Mid-sized Companies in Asia-Pacific and Rest of the World, 2024-2035 (USD Billion)
Table 25.111 Peptide TherapeuticsContract API Manufacturing Market for Large and Very Large Companies in Asia-Pacific and Rest of the World, 2024-2035 (USD Billion)
Table 25.112 Peptide TherapeuticsContract API Manufacturing Market in Asia-Pacific and Rest of the World for Chemical Synthesis Method, 2024-2035 (USD Billion)
Table 25.113 Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World for Non-Chemical Synthesis Method, 2024-2035 (USD Billion)